09:46 AM EDT, 07/23/2025 (MT Newswires) -- Avidity Biosciences ( RNA ) said Wednesday that the US Food and Drug Administration has granted breakthrough therapy designation to delpacibart zotadirsen for the treatment of Duchenne muscular dystrophy.

The biopharmaceutical company said that it remains on track to submit a biologics license application for the treatment by the end of the year.

Duchenne muscular dystrophy is a genetic condition denoted by progressive muscle damage and weakness due to the loss of dystrophin protein, Avidity Biosciences ( RNA ) said.

Price: 33.39, Change: -0.15, Percent Change: -0.43